Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
Cadrenal Therapeutics (Nasdaq: CVKD) said Phase 2 late-breaking data for its 12-LOX inhibitor CAD-1005 were presented at ISTH 2026. In HIT, CAD-1005 showed an absolute reduction of more than 25% in new or worsening thrombotic events vs placebo (50% vs >75%) and no CAD-1005-attributable serious adverse events or deaths. Company cites $2B peak annual revenue potential.
How this was made
The 30-second read
Why it matters
If the Phase 2 signal is robust enough for regulators and partners, it can improve the probability of successful Phase 3 execution and strengthen partnering leverage.
Market read
Newly presented Phase 2 efficacy and safety highlights for CAD-1005 at ISTH 2026 provide a fresh, time-sensitive catalyst for CVKD’s clinical and partnering outlook.
What to watch
Key missing details include absolute event rates, confidence intervals, and whether the endpoint definition and patient subgroups will hold up in a larger pivotal trial.
Background
HIT is an immune-mediated, prothrombotic complication where current anticoagulants reduce thrombin generation but do not directly address antibody-driven platelet activation.
Ticker impact
Cadrenal reports late-breaking ISTH Phase 2 results for CAD-1005 in HIT, citing >25% reduction in thrombotic events vs placebo.
Near-term upside bias on trial-data enthusiasm, with follow-through dependent on Phase 3 design details and statistical significance.
The article discloses new conference-presented Phase 2 highlights (efficacy, safety, and trial-design implications) but does not provide full endpoints or statistical significance, limiting conviction.
Market effects
Supports investor appetite for novel immunothrombosis mechanisms (12-LOX inhibition) and may raise attention on HIT pipeline differentiation.
Primarily US-listed biotech sentiment; conference-driven catalysts can spill into broader small-cap healthcare risk appetite.
ISTH is a global thrombosis forum, so the data may influence international clinician and partner interest in HIT therapies.
Counterpoint
The study is described as not sufficiently powered for statistical significance, so the >25% reduction may not translate into Phase 3 success.
Key entities
- companyCadrenal Therapeutics, Inc.
Nasdaq-listed biopharmaceutical company advancing CAD-1005 for heparin-induced thrombocytopenia (HIT).
- drug_candidateCAD-1005
First-in-class 12-lipoxygenase (12-LOX) inhibitor targeting immune signaling in HIT; presented as Phase 2 late-breaking data at ISTH 2026.
- conferenceISTH 2026 Congress
International Society on Thrombosis and Haemostasis meeting where the late-breaking oral abstract was presented.
